Advanced search
Publication Cover
Therapeutics and Clinical Risk Management Volume 6, 2010 - Issue
Submit an article Journal homepage
182
Views
73
CrossRef citations to date
0
Altmetric
Review

Review of mifamurtide in the treatment of patients with osteosarcoma

Leo Kager1 St. Anna Children’s Hospital, Vienna, AustriaCorrespondence[email protected]
,
Ulrike Pötschger2 Children’s Cancer Research Institute, Vienna, Austria
&
Stefan Bielack3 Klinikum Stuttgart, Olgahospital, Pediatrics 5 – Oncology, Hematology, Immunology, Stuttgart, Germany
Pages 279-286 | Published online: 15 Jun 2010

Citations (73)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Claudia Maria Hattinger, Maria Pia Patrizio, Federica Magagnoli, Silvia Luppi & Massimo Serra. (2019) An update on emerging drugs in osteosarcoma: towards tailored therapies?. Expert Opinion on Emerging Drugs 24:3, pages 153-171.
Read now
Marie-Françoise Heymann, Hannah K. Brown & Dominique Heymann. (2016) Drugs in early clinical development for the treatment of osteosarcoma. Expert Opinion on Investigational Drugs 25:11, pages 1265-1280.
Read now
Petra Maresova, Blanka Klimova & Kamil Kuca. (2016) Financial and legislative aspects of drug development of orphan diseases on the European market – a systematic review. Applied Economics 48:27, pages 2562-2570.
Read now
Pia T Johansen, Daniel Zucker, Ladan Parhamifar, Houman Pourhassan, Ditte Villum Madsen, Jonas R Henriksen, Monika Gad, Alcide Barberis, Roberto Maj, Thomas L Andresen & Simon S Jensen. (2015) Monocyte targeting and activation by cationic liposomes formulated with a TLR7 agonist. Expert Opinion on Drug Delivery 12:7, pages 1045-1058.
Read now

Articles from other publishers (69)

Nagavendra Kommineni, Ruchita Chaudhari, João Conde, Sedef Tamburaci, Berivan Cecen, Pranjal Chandra & Rajendra Prasad. (2023) Engineered Liposomes in Interventional Theranostics of Solid Tumors. ACS Biomaterials Science & Engineering 9:8, pages 4527-4557.
Crossref
Bikesh K. Nirala, Tajhal D. Patel, Lyazat Kurenbekova, Ryan Shuck, Atreyi Dasgupta, Nino Rainusso, Cristian Coarfa & Jason T. Yustein. (2023) MYC regulates CSF1 expression via microRNA 17/20a to modulate tumor-associated macrophages in osteosarcoma. JCI Insight 8:13.
Crossref
Youngcheon Song. (2023) Application of Exosome-based Drug Delivery System in Combination Anticancer Treatment. Journal of Korean Society of Health-System Pharmacists 40:2, pages 222-231.
Crossref
Ravi Teja Chitturi Suryaprakash, Mohammad Ayman Abdulkarim Safi, Noufa Alonazi, Ahdab A. Alsieedi & Omar Kujan. 2023. Molecular Targets and Cancer Therapeutics (Part 2). Molecular Targets and Cancer Therapeutics (Part 2) 165 235 .
Kathryn Cole, Zaid Al-Kadhimi & James E. Talmadge. (2023) Highlights into historical and current immune interventions for cancer. International Immunopharmacology 117, pages 109882.
Crossref
Helen Stradling. 2023. Orthopaedic and Trauma Nursing. Orthopaedic and Trauma Nursing 201 213 .
Claudia Maria Hattinger, Iris Chiara Salaroglio, Leonardo Fantoni, Martina Godel, Chiara Casotti, Joanna Kopecka, Katia Scotlandi, Toni Ibrahim, Chiara Riganti & Massimo Serra. (2023) Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma. International Journal of Molecular Sciences 24:1, pages 799.
Crossref
Tania B. Lopez-Mendez, Raffaele Strippoli, Flavia Trionfetti, Pilar Calvo, Marco Cordani & Juan Gonzalez-Valdivieso. 2023. Cancer Nanotechnology. Cancer Nanotechnology 325 383 .
Raghavendra C. Mundargi, Neetika Taneja, Jayeshkumar J. Hadia & Ajay J. Khopade. 2022. Targeted Drug Delivery. Targeted Drug Delivery 69 125 .
Francisco Rodríguez, Pablo Caruana, Noa De la Fuente, Pía Español, María Gámez, Josep Balart, Elisa Llurba, Ramón Rovira, Raúl Ruiz, Cristina Martín-Lorente, José Luis Corchero & María Virtudes Céspedes. (2022) Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges. Biomolecules 12:6, pages 784.
Crossref
Christine Schwering, Maya Niethard, Georg Gosheger, Maria Anna Smolle, Frank Traub, Simon Adam, Marcel-Philipp Henrichs, Hans Roland Dürr, Jendrik Hardes, Per-Ulf Tunn, Andreas Leithner & Dimosthenis Andreou. (2022) Are Postoperative Infections in the First 12 Months after Wide Resection and Megaprosthetic Replacement Associated with the Survival of Osteosarcoma Patients? Results of a Multicenter Study. Cancers 14:11, pages 2682.
Crossref
Fang Nan, Yutong Sun, Hantian Liang, Jingyang Zhou, Xiao Ma & Dunfang Zhang. (2022) Mannose: A Sweet Option in the Treatment of Cancer and Inflammation. Frontiers in Pharmacology 13.
Crossref
Xujun Cao, Anthony F. Cordova & Lingyin Li. (2021) Therapeutic Interventions Targeting Innate Immune Receptors: A Balancing Act. Chemical Reviews 122:3, pages 3414-3458.
Crossref
Jafrin Jobayer Sonju, Achyut Dahal & Seetharama D. Jois. 2022. Peptide Therapeutics. Peptide Therapeutics 203 235 .
Minchao Lv, Qingxin Xu, Bei Zhang, Zhiqiang Yang, Jun Xie, Jinku Guo, Feixiong He & Wei Wang. (2021) Imperatorin induces autophagy and G0/G1 phase arrest via PTEN-PI3K-AKT-mTOR/p21 signaling pathway in human osteosarcoma cells in vitro and in vivo. Cancer Cell International 21:1.
Crossref
Seung Rim Hwang, Kushal Chakraborty, Jeong Man An, Jagannath Mondal, Hong Yeol Yoon & Yong-kyu Lee. (2021) Pharmaceutical Aspects of Nanocarriers for Smart Anticancer Therapy. Pharmaceutics 13:11, pages 1875.
Crossref
Hongfei Jiang, Xiaofei Qin, Qi Wang, Qi Xu, Jie Wang, Yudong Wu, Wujun Chen, Chao Wang, Tingting Zhang, Dongming Xing & Renshuai Zhang. (2021) Application of carbohydrates in approved small molecule drugs: A review. European Journal of Medicinal Chemistry 223, pages 113633.
Crossref
Giorgia Giordano, Alessandra Merlini, Giulio Ferrero, Giulia Mesiano, Erika Fiorino, Silvia Brusco, Maria Laura Centomo, Valeria Leuci, Lorenzo D’Ambrosio, Massimo Aglietta, Dario Sangiolo, Giovanni Grignani & Ymera Pignochino. (2021) EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing’s Sarcoma and Chondrosarcoma. Cells 10:11, pages 2893.
Crossref
Danielle E. Large, Rudolf G. Abdelmessih, Elizabeth A. Fink & Debra T. Auguste. (2021) Liposome composition in drug delivery design, synthesis, characterization, and clinical application. Advanced Drug Delivery Reviews 176, pages 113851.
Crossref
Peter Múdry, Michal Kýr, Ondřej Rohleder, Michal Mahdal, Iva Staniczková Zambo, Marta Ježová, Tomáš Tomáš & Jaroslav Štěrba. (2021) Improved osteosarcoma survival with addition of mifamurtide to conventional chemotherapy – Observational prospective single institution analysis. Journal of Bone Oncology 28, pages 100362.
Crossref
Noelia Nieto González, Antonella Obinu, Giovanna Rassu, Paolo Giunchedi & Elisabetta Gavini. (2021) Polymeric and Lipid Nanoparticles: Which Applications in Pediatrics?. Pharmaceutics 13:5, pages 670.
Crossref
Marie‐Françoise Heymann, Kristina Schiavone & Dominique Heymann. (2020) Bone sarcomas in the immunotherapy era. British Journal of Pharmacology 178:9, pages 1955-1972.
Crossref
Tomohiro Fujiwara, John Healey, Koichi Ogura, Aki Yoshida, Hiroya Kondo, Toshiaki Hata, Miho Kure, Hiroshi Tazawa, Eiji Nakata, Toshiyuki Kunisada, Toshiyoshi Fujiwara & Toshifumi Ozaki. (2021) Role of Tumor-Associated Macrophages in Sarcomas. Cancers 13:5, pages 1086.
Crossref
Binbin Zheng & Wei Lu. 2021. Nanoparticle-Mediated Immunotherapy. Nanoparticle-Mediated Immunotherapy 191 208 .
Bin Liu, Shuqiang Yao & Jiping Zhou. (2020) Micro-RNA 122 and micro-RNA 96 affected human osteosarcoma biological behavior and associated with prognosis of patients with osteosarcoma. Bioscience Reports 40:12.
Crossref
Cosmas Rinaldi Adithya Lesmana & Baiq Kirana D. Mandasari. 2020. Immunosuppression. Immunosuppression.
Yao Ma, Jingshu Yang, Xiduan Wei, Yameng Pei, Jingjia Ye, Xueyuan Li, Guangxu Si, Jingyuan Tian, Yi Dong & Gang Liu. (2020) Nonpeptidic quinazolinone derivatives as dual nucleotide-binding oligomerization domain-like receptor 1/2 antagonists for adjuvant cancer chemotherapy. European Journal of Medicinal Chemistry 207, pages 112723.
Crossref
Ingrid Lilienthal & Nikolas Herold. (2020) Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies. International Journal of Molecular Sciences 21:18, pages 6885.
Crossref
Nina E. Murugina, Anna S. Budikhina, Yulia A. Dagil, Polina V. Maximchik, Lyudmila S. Balyasova, Vladimir V. Murugin, Mikhail V. Melnikov, Viktoriya S. Sharova, Anna M. Nikolaeva, Georgy Z. Chkadua, Boris V. Pinegin & Mikhail V. Pashenkov. (2020) Glycolytic reprogramming of macrophages activated by NOD1 and TLR4 agonists: No association with proinflammatory cytokine production in normoxia. Journal of Biological Chemistry 295:10, pages 3099-3114.
Crossref
Maria Letizia Taddei, Laura Pietrovito, Angela Leo & Paola Chiarugi. (2020) Lactate in Sarcoma Microenvironment: Much More than just a Waste Product. Cells 9:2, pages 510.
Crossref
Mohammad Norouzi, Mehrnaz Amerian, Mahshid Amerian & Fatemeh Atyabi. (2020) Clinical applications of nanomedicine in cancer therapy. Drug Discovery Today 25:1, pages 107-125.
Crossref
Luke Tattersall, Zoe Davison & Alison Gartland. 2020. Encyclopedia of Bone Biology. Encyclopedia of Bone Biology 362 378 .
Raoud Marayati, Colin H. Quinn & Elizabeth A. Beierle. (2019) Immunotherapy in Pediatric Solid Tumors—A Systematic Review. Cancers 11:12, pages 2022.
Crossref
Shuli FanXiang GaoPeng ChenXu Li. (2019) Carboxypeptidase E-ΔN promotes migration, invasiveness, and epithelial–mesenchymal transition of human osteosarcoma cells via the Wnt–β-catenin pathway. Biochemistry and Cell Biology 97:4, pages 446-453.
Crossref
Debarshi Banerjee, Artur Cieslar-Pobuda, Geyunjian Harry Zhu, Emilia Wiechec & Hirak K. Patra. (2019) Adding Nanotechnology to the Metastasis Treatment Arsenal. Trends in Pharmacological Sciences 40:6, pages 403-418.
Crossref
Rosana Ribić, Ivan Kodrin, Ivana Biljan, Marija Paurević & Srđanka Tomić. (2018) Ten-membered rings as key interaction motifs in folding of desmuramyl di-, tri-, and tetrapeptides. Structural Chemistry 30:3, pages 743-754.
Crossref
Bushra Abu-Helil & Louise van der Weyden. (2019) Metastasis in the wild: investigating metastasis in non-laboratory animals. Clinical & Experimental Metastasis 36:1, pages 15-28.
Crossref
Bomy Lee Chung, Joseph Kaplinsky, Robert Langer & Nazila Kamaly. 2019. Nanotheranostics for Cancer Applications. Nanotheranostics for Cancer Applications 163 205 .
Isabel Sousa, Filipa Rodrigues, Hugo Prazeres, Raquel T. Lima & Paula Soares. (2018) Liposomal therapies in oncology: does one size fit all?. Cancer Chemotherapy and Pharmacology 82:5, pages 741-755.
Crossref
Yangjin Bae, Huan‐Chang Zeng, Linchao Lu, Lisa L. Wang & Brendan Lee. 2018. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism 768 774 .
Yulia A. Dagil, Viktoriya S. Sharova, Boris V. Pinegin & Mikhail V. Pashenkov. (2018) A cell-based test system for the assessment of pharmacokinetics of NOD1 and NOD2 receptor agonists. International Immunopharmacology 63, pages 94-100.
Crossref
Mary Frances Wedekind, Nicholas L. Denton, Chun-Yu Chen & Timothy P. Cripe. (2018) Pediatric Cancer Immunotherapy: Opportunities and Challenges. Pediatric Drugs 20:5, pages 395-408.
Crossref
Carlos Rodríguez-Nogales, Yolanda González-Fernández, Azucena Aldaz, Patrick Couvreur & María J. Blanco-Prieto. (2018) Nanomedicines for Pediatric Cancers. ACS Nano 12:8, pages 7482-7496.
Crossref
Nurdan Tacyildiz, Sonay Incesoy Ozdemir, Emel Unal, Melda Berber, Handan Dincaslan & Gulsan Yavuz. (2018) The Efficiency and Toxicity of Mifamurtide in Childhood Osteosarcoma. Journal of Pediatric Hematology/Oncology 40:6, pages e373-e376.
Crossref
Zongze Wang, Ying Li, Fengxin Zhou, Zhe Piao & Jian Hao. (2018) β‑elemene enhances anticancer bone neoplasms efficacy of paclitaxel through regulation of GPR124 in bone neoplasms cells. Oncology Letters.
Crossref
Ana Sebio, Breelyn A Wilky, Vicki L Keedy & Robin L Jones. (2018) The current landscape of early drug development for patients with sarcoma in the immunotherapy era. Future Oncology 14:12, pages 1197-1211.
Crossref
Kangmao Huang, Yanyan Chen, Rui Zhang, Yizheng Wu, Yan Ma, Xiangqian Fang & Shuying Shen. (2018) Honokiol induces apoptosis and autophagy via the ROS/ERK1/2 signaling pathway in human osteosarcoma cells in vitro and in vivo. Cell Death & Disease 9:2.
Crossref
Lirong Zhang, Xiaohua Xu, Tiechao Jiang, Kunzhe Wu, Chuanbo Ding, Zhen Liu, Xuanhe Zhang, Tianhua Yu & Changlong Song. (2018) Citrus aurantium Naringenin Prevents Osteosarcoma Progression and Recurrence in the Patients Who Underwent Osteosarcoma Surgery by Improving Antioxidant Capability . Oxidative Medicine and Cellular Longevity 2018, pages 1-16.
Crossref
Mikhail V. Pashenkov, Yulia A. Dagil & Boris V. Pinegin. (2018) NOD1 and NOD2: Molecular targets in prevention and treatment of infectious diseases. International Immunopharmacology 54, pages 385-400.
Crossref
Jenna S. Bleloch, Reyna D. Ballim, Serah Kimani, Jeannette Parkes, Eugenio Panieri, Tarryn Willmer & Sharon Prince. (2017) Managing sarcoma: where have we come from and where are we going?. Therapeutic Advances in Medical Oncology 9:10, pages 637-659.
Crossref
Rincy Jimmy, Cindy Stern, Karolina Lisy & Sarahlouise White. (2017) Effectiveness of mifamurtide in addition to standard chemotherapy for high-grade osteosarcoma: a systematic review. JBI Database of Systematic Reviews and Implementation Reports 15:8, pages 2113-2152.
Crossref
Joseph F. Cavallari, Morgan D. Fullerton, Brittany M. Duggan, Kevin P. Foley, Emmanuel Denou, Brennan K. Smith, Eric M. Desjardins, Brandyn D. Henriksbo, Kalvin J. Kim, Brian R. Tuinema, Jennifer C. Stearns, David Prescott, Philip Rosenstiel, Brian K. Coombes, Gregory R. Steinberg & Jonathan D. Schertzer. (2017) Muramyl Dipeptide-Based Postbiotics Mitigate Obesity-Induced Insulin Resistance via IRF4. Cell Metabolism 25:5, pages 1063-1074.e3.
Crossref
Leo Kager, Gevorg Tamamyan & Stefan Bielack. (2017) Novel insights and therapeutic interventions for pediatric osteosarcoma. Future Oncology 13:4, pages 357-368.
Crossref
Ratesh Khillan, Mohan Preet, Tanya DiFrancesco, Uchechi Uzoegwu, Osman Ali & Aditya V. Maheshwari. 2017. Sarcoma. Sarcoma 439 457 .
Lu Xie, Wei Guo, Xiaodong Tang, Yi Yang & Jie Xu. (2016) Effects of Arsenic Trioxide on Minor Progressive High-Grade Osteosarcoma of the Extremities Metastatic to the Lung: Results of 39 Patients Treated in a Single Institution. Case Reports in Oncology 9:3, pages 610-628.
Crossref
Christina K Lettieri, Nicole Appel, Nicole Labban, Danielle M Lussier, Joseph N Blattman & Pooja Hingorani. (2016) Progress and opportunities for immune therapeutics in osteosarcoma. Immunotherapy 8:10, pages 1233-1244.
Crossref
JIA WAN, XIANGHONG ZHANG, TANG LIU & XIANGSHENG ZHANG. (2016) Strategies and developments of immunotherapies in osteosarcoma. Oncology Letters 11:1, pages 511-520.
Crossref
Alberto Benito-Martin, Angela Di Giannatale, Sophia Ceder & Héctor Peinado. (2015) The New Deal: A Potential Role for Secreted Vesicles in Innate Immunity and Tumor Progression. Frontiers in Immunology 6.
Crossref
Xiaodong Mu, Daniel Brynien & Kurt R. Weiss. (2015) The HDAC Inhibitor Vorinostat Diminishes the In Vitro Metastatic Behavior of Osteosarcoma Cells . BioMed Research International 2015, pages 1-6.
Crossref
Liangdong Jiang, Aiyong He, Qing Zhang & Cheng Tao. (2014) miR-126 inhibits cell growth, invasion, and migration of osteosarcoma cells by downregulating ADAM-9. Tumor Biology 35:12, pages 12645-12654.
Crossref
Helen Stradling. 2014. Orthopaedic and trauma nursing. Orthopaedic and trauma nursing 184 197 .
Sergei R. Guma, Dean A. Lee, Yu Ling, Nancy Gordon & Eugenie S. Kleinerman. (2014) Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis. Pediatric Blood & Cancer 61:8, pages 1362-1368.
Crossref
Alejandro Sosnik & Angel M. Carcaboso. (2014) Nanomedicines in the future of pediatric therapy. Advanced Drug Delivery Reviews 73, pages 140-161.
Crossref
Rincy Jimmy, Sarahlouise White & Karolina Lisy. (2014) Effectiveness of mifamurtide in addition to standard chemotherapy for high-grade osteosarcoma: a systematic review protocol. JBI Database of Systematic Reviews and Implementation Reports 12:11, pages 61-73.
Crossref
Sukhvinder Johal, Stephen Ralston & Christopher Knight. (2013) Mifamurtide for High-Grade, Resectable, Nonmetastatic Osteosarcoma Following Surgical Resection: A Cost-Effectiveness Analysis. Value in Health 16:8, pages 1123-1132.
Crossref
Gábor Mezo. 2013. Amino Acids, Peptides and Proteins. Amino Acids, Peptides and Proteins 203 252 .
J PosthumaDeBoer, B.J van Royen & M.N Helder. (2013) Mechanisms of therapy resistance in osteosarcoma: a review. Oncology Discovery 1:1, pages 8.
Crossref
J E Davies, S Neidle & D G Taylor. (2012) Developing and paying for medicines for orphan indications in oncology: utilitarian regulation vs equitable care?. British Journal of Cancer 106:1, pages 14-17.
Crossref
Uwe Fricke & Ulrich Schwabe. 2011. Arzneiverordnungs-Report 2011. Arzneiverordnungs-Report 2011 43 117 .

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.